Abstract:Comparative genomic in situ hybridization (CGH) provides a new possibility for searching genomes for imbalanced genetic material. Labeled genomic test DNA, prepared from clinical or tumor specimens, is mixed with differently labeled control DNA prepared from cells with normal chromosome complements. The mixed probe is used for chromosomal in situ suppression (CISS) hybridization to normal metaphase spreads (CGH-metaphase spreads). Hybridized test and control DNA sequences are detected via different fluorochromes, e.g., fluorescein isothiocyanate (FITC) and tetraethylrhodamine isothiocyanate (TRITC). The ratios of FITC/TRITC fluorescence intensities for each chromosome or chromosome segment should then reflect its relative copy number in the test genome compared with the control genome, e.g., 0.5 for monosomies, 1 for disomies, 1.5 for trisomies, etc. Initially, model experiments were designed to test the accuracy of fluorescence ratio measurements on single chromosomes. DNAs from up to five human chromosome-specific plasmid libraries were labeled with biotin and digoxigenin in different hapten proportions. Probe mixtures were used for CISS hybridization to normal human metaphase spreads and detected with FITC and TRITC. An epifluorescence microscope equipped with a cooled charge coupled device (CCD) camera was used for image acquisition. Procedures for fluorescence ratio measurements were developed on the basis of commercial image analysis software. For hapten ratios 4/1, 1/1 and 1/4, fluorescence ratio values measured for individual chromosomes could be used as a single reliable parameter for chromosome identification. Our findings indicate (1) a tight correlation of fluorescence ratio values with hapten ratios, and (2) the potential of fluorescence ratio measurements for multiple color chromosome painting. Subsequently, genomic test DNAs, prepared from a patient with Down syndrome, from blood of a patient with T-cell prolymphocytic leukemia, and from cultured cells of a renal papillary carcinoma cell line, were applied in CGH experiments. As expected, significant differences in the fluorescence ratios could be measured for chromosome types present in different copy numbers in these test genomes, including a trisomy of chromosome 21, the smallest autosome of the human complement. In addition, chromosome material involved in partial gains and losses of the different tumors could be mapped to their normal chromosome counterparts in CGH-metaphase spreads. An alternative and simpler evaluation procedure based on visual inspection of CCD images of CGH-metaphase spreads also yielded consistent results from several independent observers. Pitfalls, methodological improvements, and potential applications of CGH analyses are discussed.

The Application of Universal Linkage System in Comparative Genomic Hybridization of Formalin-fixed, Paraffin-embedded Bladder Cancer Tissues

Chromosome aberration of urine exfoliated cells to diagnose bladder neoplasm by fluorescence in situ hybridization

Aberrations of chromosomes 3,7,17 and 9p21 locus and its clinical significance in urothelial carcinoma of bladder

Application of Double Fluorescence in Situ Hybridization Technology in the Diagnosis of Bladder Urothelial Carcinoma

Detection of chromosomal alterations in bladder transitional cell carcinomas from Northern China by comparative genomic hybridization.

The Clinical Application of Fluorescence in Situ Hybridization in Diagnosing Urothelial Carcinoma

The clinical application of fluoresence in situ hybridization in diagnosis of urothelial bladder cancer

Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization

Distinguishing Urothelial Carcinoma in the Upper Urinary Tract from Benign Diseases with Hematuria Using FISH.

Utility of fluorescence in situ hybridization analysis for detecting upper urinary tract-urothelial carcinoma

Roles of fluorescence in situ hybridization in differential diagnosis of urothelial carcinoma in upper urinary tract from benign diseases with hematuria

Superior Molecular Pathology of Urothelial Bladder Cancer Using Urinary Cell-Free DNA.

The combined application of urinary liquid-based cytology with fluorescence in situ hybridization and p16/Ki-67 dual immunostaining is valuable for improving the early diagnosis of upper tract urothelial carcinomas

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

Application of Comparative Genomic Hybridization (CGH) in the Genetic Analysis of Lymphoma

Analysis of Chromosomal Alterations in Urothelial Carcinoma

Applying fragmentomics profiles of urinary cell-free DNA for bladder cancer detection.

Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study

Clinical diagnostic study of UCA1 gene for bladder urothelial carcinoma

Advancement in Study on Comparative Genomic Hybridization

Study on the detection of bladder cancer by fluorescence in situ hybridization